Interim Chief Executive Officer and President
Vice President of Finance and Chief Accounting Officer
Kevin has been Vice President of Finance and Chief Accounting Officer since 2014. Previously, he was Vice President, Finance and Administration for Avaxia Biologics, a clinical-stage biopharmaceutical company developing gut-targeted therapeutics. Prior to joining Avaxia, he served from 2009 to 2013 at various biotechnology and medical device companies in interim Vice President of Finance and Controller roles. From 2005 to 2009, Kevin was the Corporate Controller and Principal Accounting Officer of NitroMed, a publicly traded cardiovascular-focused pharmaceutical company. Kevin earned a B.S. in business management from the University of Hartford, an M.B.A. from Boston University and an M.A. in accounting from Suffolk University. He is a certified public accountant in the Commonwealth of Massachusetts.
Chairman of the Board
Wael has served as Enumeral’s Chairman since September 2016, and served as the company’s President and Chief Executive Officer from September 2016 until June 2017. Wael has over than two decades of senior executive and business development experience in the life sciences industry. From 2001 to 2014, he held positions of increasing responsibility at Forest Laboratories, Inc., culminating as Corporate Vice President, Global Business Development. In that role, he was responsible for business development and alliance management, including the identification, assessment and negotiation of multiple business opportunities. Wael helped build and manage a broad network of partnerships at Forest, and upon Forest’s acquisition by Actavis, he also assisted with the integration of the two companies. Wael was subsequently engaged in a number of entrepreneurial ventures, including helping to launch Valentine & Cautreels, Inc., a start-up company focusing on improving healthcare outcomes and reducing the total cost of care. He continues to serve on Valentine & Cautreels’ advisory board. Prior to Forest, Wael served in positions of increasing responsibility at Schering-Plough and Novartis in the fields of sales, marketing, and new product development. Wael holds a B.S. in biology from the American University of Beirut, and an M.B.A. from Concordia University.
Former Chief Financial Officer, OSI Pharmaceuticals
Mr. Van Nostrand has been a member of our Board of Directors since 2014. He is a seasoned biotechnology executive with an extensive background in finance, operations and accounting in public biotechnology companies in all stages of development. Most recently, Mr. Van Nostrand held senior executive positions with AGI Dermatics and Aureon BioSciences. For 21 years, he served in executive leadership positions at OSI Pharmaceuticals, including Chief Compliance Officer, Chief Financial Officer and Chief Accounting Officer. During his tenure with OSI Pharmaceuticals, he had financial responsibility for all of its significant operations and was instrumental in development of strategy, budgeting and forecasting, negotiation and closing of several major corporate collaborations, and SEC reporting. During his tenure, Mr. Van Nostrand led the OSI financial team in raising over $1.4 billion in equity and debt during a time of high growth as OSI transitioned from an early-stage biotechnology company to a multi-billion dollar, commercial-stage organization. Prior to joining OSI, he was a manager at Touche Ross & Co (currently Deloitte). Mr. Van Nostrand currently serves on the boards of several other publicly traded biotechnology companies, including Metabolix, where he is chairman, Achillion Pharmaceuticals and Intra-Cellular Therapies. Mr. Van Nostrand also serves as the chairman of the audit committee for each of these companies. In addition, Mr. Van Nostrand serves on the board of directors of the Biomedical Research Alliance of New York. He is the former Chairman, and currently serves on the board, of NYBio (formerly the New York Biotechnology Association) and also serves on the Foundation Board of Farmingdale University. Mr. Van Nostrand received a B.S. in accounting from Long Island University and studied management at The Wharton School of the University of Pennsylvania. He is a Certified Public Accountant. He is a member of Enumeral's Audit Committee, Compensation Committee, and Nominating and Governance Committee.